Estonian 
English 
Arabic 
Bulgarian 
Czech 
Dutch 
Finnish 
French 
German 
Hungarian 
Italian 
Japanese 
Korean 
Norwegian 
Polish 
Portuguese 
Russian 
Serbian 
Slovak 
Slovenian 
Spanish 
Swedish 
Thai 
The nutraceutical and functional food industry continues to advance with increasing demand for scientifically validated compounds that deliver measurable health benefits while maintaining excellent safety profiles. Among bioactive compounds gaining significant recognition, 1-Deoxynojirimycin hydrochloride is supported by preclinical and clinical research on DNJ-containing mulberry extracts, which demonstrate well-characterized α-glucosidase inhibition mechanisms associated with healthy glucose metabolism. This naturally derived compound has established strong credibility in the nutritional supplement and functional food industries for its unique ability to support healthy blood sugar levels, particularly when formulated with complementary ingredients in advanced nutraceutical systems.
Unlike single-pathway synthetic compounds, 1-deoxynojirimycin hcl works through fundamental carbohydrate metabolism processes to support the body's natural glucose regulation mechanisms. Research suggests that DNJ-containing extracts may help modulate postprandial glucose responses; however, evidence for long-term metabolic wellness effects remains limited and requires further investigation. With growing demand for scientifically supported nutritional ingredients, 1-Deoxynojirimycin hydrochloride is increasingly incorporated into advanced nutraceutical formulations, particularly alongside complementary actives targeting multiple metabolic pathways.
What is 1-Deoxynojirimycin Hydrochloride?
1-Deoxynojirimycin hydrochloride (1-DNJ·HCl) is a naturally occurring iminosugar compound derived from mulberry leaves (Morus alba) and other botanical sources. This bioactive compound contains a unique molecular structure that mimics glucose, enabling it to interact with specific enzymes involved in carbohydrate digestion and metabolism. The hydrochloride salt form enhances stability and bioavailability for nutraceutical applications.
Unlike conventional glucose management compounds that function through single mechanisms, 1deoxynojirimycin hydrochloride provides comprehensive metabolic support through α-glucosidase inhibition, carbohydrate absorption modulation, and glucose homeostasis support. This versatile ingredient is naturally abundant in mulberry leaves, where traditional use has been optimized through modern extraction and purification technologies for nutraceutical applications.
The body's metabolic systems respond to this bioactive compound through well-characterized enzyme inhibition pathways involving intestinal carbohydrate processing and glucose absorption regulation. While the body naturally produces various glucose regulation mechanisms, supplementation with standardized 1-DNJ·HCl can support optimal metabolic function and healthy blood sugar maintenance.
Specification Sheet Reference:
| Property | Details |
|---|---|
| Type | Iminosugar compound |
| CAS Number | 57126-62-2 |
| Appearance | White to off-white crystalline powder |
| Molecular Formula | C₆H₁₄ClNO₄ |
| Molecular Weight | ~199.6 g/mol |
| Purity | ≥95% (HPLC) |
| Solubility | Freely soluble in water |
| MOQ | 25kg+ |
| Sample | Available (10–20g/bag) |
| OEM/ODM Service | Available |
| Test Methods | HPLC/NIR available. Contact the sales team for details. |
| Certifications | ISO available. Contact the sales team for details. |
Mechanism of Action
1-Deoxynojirimycin hydrochloride supports blood sugar regulation by directly influencing the digestive phase of carbohydrate metabolism. As an iminosugar with a molecular structure similar to glucose, DNJ HCl competitively and reversibly binds to intestinal α-glucosidase enzymes located along the brush border of the small intestine. These enzymes are responsible for hydrolyzing oligosaccharides and disaccharides into absorbable monosaccharides. By temporarily reducing enzymatic activity, DNJ HCl slows the rate at which dietary carbohydrates are converted into glucose, resulting in a more gradual glucose appearance in the bloodstream following meals. This localized, enzyme-specific interaction is well documented in in vitro assays and animal models, and is supported by human intervention studies using DNJ-rich mulberry extracts.
Through this modulation of carbohydrate hydrolysis, DNJ HCl influences postprandial glucose and insulin dynamics without directly stimulating insulin secretion or altering insulin receptor signaling. Clinical research involving DNJ-containing extracts has demonstrated attenuated post-meal glucose and insulin responses during sucrose and carbohydrate challenge tests, indicating that DNJ acts upstream of systemic glucose handling. Importantly, DNJ HCl exhibits reversible enzyme binding, allowing normal digestive processes to resume once the compound passes through the intestinal tract. This transient mode of action helps preserve physiological carbohydrate digestion while contributing to the favorable tolerance profiles reported across preclinical and early human studies.
Beyond its primary digestive-phase activity, DNJ HCl plays a complementary role within multi-pathway blood sugar support systems. By limiting the initial rate of glucose entry into circulation, it creates a metabolic context in which downstream ingredients targeting glucose transport, cellular uptake, or energy metabolism can function more effectively. While direct human trials evaluating isolated DNJ HCl remain limited, its consistent biochemical behavior and alignment with extract-based clinical evidence support its use as a precisely defined ingredient for blood sugar regulation in advanced health-focused formulation strategies.
Benefits and Safety Profile of 1-Deoxynojirimycin Hydrochloride in Nutraceutical Applications
1-Deoxynojirimycin hcl supports metabolic health through four key pathways that are well-documented in clinical and biochemical research. These mechanisms collectively support glucose metabolism, carbohydrate processing, metabolic efficiency, and overall wellness, making it a valuable bioactive ingredient in nutraceutical formulations.
- α-Glucosidase Inhibition and Carbohydrate Processing Support: 1deoxynojirimycin hydrochloride functions as a competitive inhibitor of intestinal α-glucosidase enzymes, which are responsible for breaking down complex carbohydrates into simple sugars. This mechanism supports healthy postprandial glucose responses by modulating the rate of carbohydrate digestion and absorption. Clinical studies demonstrate that this inhibition occurs through reversible enzyme binding without permanent metabolic disruption.
- Postprandial Glucose Response Modulation: By influencing carbohydrate absorption kinetics, 1-DNJ·HCl supports smoother postprandial glucose curves and helps maintain glucose levels within normal ranges. Research indicates that this compound can contribute to healthy glucose metabolism when used as part of a comprehensive nutritional approach, particularly beneficial for individuals seeking metabolic wellness support.
- Metabolic Efficiency and Energy Balance: The compound supports optimal metabolic function by influencing how the body processes dietary carbohydrates, potentially contributing to improved energy utilization and metabolic efficiency. This mechanism helps maintain stable energy levels throughout the day while supporting healthy weight management as part of a balanced lifestyle.
- Antioxidant and Cellular Protection Support: 1deoxynojirimycin hcl demonstrates antioxidant properties that help protect cellular structures from oxidative stress associated with glucose metabolism. This protection supports long-term metabolic health and contributes to overall wellness through cellular defense mechanisms.
Safety and Potential Side Effects of 1-Deoxynojirimycin Hydrochloride
1-Deoxynojirimycin hydrochloride is generally well tolerated based on available human and preclinical research conducted with DNJ-rich mulberry leaf preparations. Short-term and repeated-use studies report a favorable safety profile, with no serious adverse effects observed at commonly studied intake levels. Mild gastrointestinal effects, such as bloating, soft stools, or transient digestive discomfort, have been reported in some cases and are consistent with DNJ’s mechanism of slowing carbohydrate digestion in the intestine. These effects appear to be dose-dependent and may be reduced through gradual introduction and appropriate formulation design.
Quality-controlled DNJ HCl grades are produced under standardized manufacturing conditions to ensure consistent purity and low impurity levels. Responsible suppliers conduct routine analytical testing to confirm identity, purity, and stability, along with screening for heavy metals, residual solvents, and microbial contamination. When sourced from qualified manufacturers and incorporated appropriately, DNJ HCl aligns with general safety expectations for ingredients used to support carbohydrate metabolism and post-meal blood sugar management.
Regulatory and FDA Status
In the United States, DNJ-containing ingredients derived from mulberry leaf have a documented history of use in food and health-related products and are commonly positioned using structure-function language related to carbohydrate metabolism and postprandial glucose handling. DNJ HCl is typically marketed within existing dietary ingredient frameworks, with compliance supported through supplier documentation, safety data, and adherence to good manufacturing practices. Companies verify regulatory alignment by confirming ingredient identity, purity, and contaminant limits in line with FDA expectations for dietary ingredients.
Internationally, regulatory classification of DNJ-containing materials varies by region and is influenced by factors such as source material, degree of purification, and intended use. In the European Union and parts of the Asia-Pacific region, mulberry-derived ingredients may be evaluated under food or novel food regulations depending on processing methods. Markets such as Japan and Canada assess DNJ-containing ingredients within existing food ingredient or health product frameworks, subject to regional safety and quality standards. Comprehensive technical documentation, including Certificates of Analysis, traceability records, and contaminant testing, supports global market acceptance and facilitates formulation approval across jurisdictions.
Clinical Research and Scientific Validation
Extensive preclinical and clinical research supports the glucose-management potential of 1-Deoxynojirimycin (DNJ), a natural iminosugar found in Morus alba (mulberry) leaves. DNJ primarily acts as an α-glucosidase inhibitor, slowing carbohydrate digestion and reducing postprandial glucose elevation without disturbing normal metabolic function.
While most human trials use DNJ-rich mulberry extracts, the isolated DNJ hydrochloride (DNJ HCl) form shares identical structural and biochemical properties, supporting comparable functional outcomes.
The following verified studies demonstrate DNJ's metabolic and safety benefits:
| Study Type | Population | DNJ Source | Duration | Key Findings | Reference |
| Clinical (Mulberry powder) | Healthy adults | DNJ-enriched mulberry powder (≈6–18 mg DNJ) | Single dose | Significantly suppressed postprandial blood glucose and insulin levels | Kimura T et al., J Nutr Sci Vitaminol 2007 |
| Clinical (Mulberry extract) | Type 2 diabetic & control subjects | Mulberry leaf extract | Acute (75 g sucrose challenge) | Reduced postprandial glucose and breath hydrogen; supported carbohydrate digestion modulation | Mudra M et al., Eur J Clin Nutr 2007 |
| Clinical (Mulberry extract) | Hyperlipidemic adults | DNJ-rich mulberry leaf extract (12 mg × 3/day) | 12 weeks | Improved lipid profile and showed excellent safety/tolerance | Kojima Y et al., J Oleo Sci 2010 |
| Clinical (Randomized Controlled Trial) | Adults with impaired glucose metabolism | Mulberry leaf extract (standardized for DNJ content) | Single administration | Observed post-meal glucose and insulin modulation | Takahashi M et al., Eur J Clin Nutr 2023 |
| Preclinical (Animal) | Diabetic mice | Isolated DNJ | 8 weeks | Improved insulin sensitivity and glucose utilization | Oku T et al., J Nutr Biochem 2006 |
| Mechanistic (In vitro/in vivo) | Enzyme inhibition assays | Purified DNJ | — | Confirmed α-glucosidase and sucrase inhibition mechanisms | Kimura T et al., Biosci Biotechnol Biochem 2004 |
Overall, these studies provide reproducible preclinical and early clinical evidence that DNJ-rich mulberry extracts support glucose metabolism primarily through α-glucosidase inhibition.
Comparison with Other Glucose Management Compounds
The following comparison outlines commonly used metabolic health ingredients based on their primary physiological pathways, product and market positioning, and key formulation considerations. This overview is intended to support manufacturers and formulators in evaluating ingredient roles within glucose-focused systems, particularly when designing differentiated and functional food formulations.
| Ingredient | Primary Physiological Pathway | Product & Market Positioning | Key Formulation Considerations |
|---|---|---|---|
| 1-Deoxynojirimycin HCl | Competitive inhibition of intestinal α-glucosidase enzymes, moderating carbohydrate hydrolysis and absorption | Positioned for postprandial glucose modulation and digestive-phase metabolic support; suitable for non-stimulant, precision metabolic formulations and premium glucose management concepts | High specificity allows low sensory impact; performs best in combination systems targeting insulin sensitivity or cellular glucose utilization; standardized purity critical for reproducibility |
| Chromium | Modulation of insulin signaling and glucose uptake pathways | Commonly positioned for long-term metabolic balance and insulin sensitivity support; widely accepted in mainstream metabolic and wellness products | Trace mineral dosing requires regulatory alignment; bioavailability depends on chromium form (e.g., picolinate, nicotinate); often used as a supportive rather than primary active |
| Gymnema Extract | Inhibition of intestinal glucose transporters and sweet taste receptors | Typically positioned in botanical glucose management or sugar-control formulations; aligns with appetite and craving management narratives | Botanical variability requires careful standardization; taste-masking often necessary; synergistic with digestive-phase actives such as DNJ HCl |
| Bitter Melon Extract | Multi-pathway metabolic activity including glucose uptake and insulin-related pathways | Positioned for broad-spectrum metabolic and traditional wellness applications rather than targeted postprandial control | Active content varies by extract type; stronger sensory profile may limit inclusion levels; commonly used in polyherbal systems |
| Alpha-Lipoic Acid | Mitochondrial redox regulation and support of cellular energy metabolism | Positioned as a foundational metabolic and antioxidant ingredient rather than an acute glucose-modulating agent | Stability and oxidation control are key formulation considerations; typically used in longer-term metabolic health or anti-aging concepts |
| Berberine | Activation of AMPK-related metabolic pathways influencing glucose and lipid metabolism | Often positioned in advanced metabolic and cardiometabolic formulations with stronger clinical narratives | Gastrointestinal tolerance may limit dose; interactions with other actives require careful formulation strategy; regulatory scrutiny varies by region |
Cinnamon Extract: The Synergistic Partner for Enhanced Metabolic Support
Cinnamon extract represents an exceptionally complementary ingredient to 1deoxynojirimycin hydrochloride in comprehensive metabolic support formulations. While 1-DNJ·HCl optimizes carbohydrate processing through specific enzyme inhibition, cinnamon extract supports glucose metabolism through insulin sensitivity enhancement and cellular glucose uptake mechanisms. This complementary relationship creates a synergistic effect where the primary compound provides targeted carbohydrate management while cinnamon ensures enhanced cellular glucose utilization and metabolic efficiency.
Combining 1-deoxynojirimycin hcl with standardized cinnamon extract has demonstrated superior outcomes in metabolic support studies compared to either ingredient used in isolation. Formulations containing both compounds may provide more comprehensive glucose management support through complementary mechanisms affecting both absorption and cellular utilization phases of glucose metabolism.
From a formulation perspective, 1-DNJ·HCl and cinnamon extract demonstrate excellent compatibility profiles across various delivery formats, with their different mechanisms enabling comprehensive metabolic support. The enzyme inhibition effects of the primary compound typically manifest within 30-60 minutes, while cinnamon's metabolic benefits develop over 2-4 weeks of consistent use. This dual approach enables the development of premium nutraceutical products targeting complete metabolic optimization for both immediate and sustained glucose management support.
1-Deoxynojirimycin Hydrochloride in the Evolving Landscape
The market landscape for blood sugar regulation and glucose management ingredients is expanding rapidly, underpinned by the rising global prevalence of diabetes and increasing interest in preventive health solutions. The broader blood sugar supplements market (which encompasses ingredients formulated to support healthy glucose responses) was valued at approximately USD 15 billion in 2023 and is projected to reach around USD 25 billion by 2032, growing at a CAGR of about 5.5% during 2024–2032. This growth is driven by heightened awareness of metabolic health, lifestyle-related disease risk, and demand for natural and mechanism-based ingredient solutions.
Within this space, products positioned for postprandial glucose modulation and carbohydrate processing are significant subsegments of the broader glucose management ecosystem, which analysts estimate to be worth USD 9.4 billion globally in 2024, with forecasts to reach USD 12.7 billion by 2030 at a CAGR of ~5.1%. The U.S. market alone has an estimated value of USD 2.6 billion for glucose management supplements, while China is forecast to grow robustly, driven by increased health awareness and preventive nutrition demand.
At a more focused ingredient level, the 1-Deoxynojirimycin (DNJ) market—reflective of demand for specific enzyme-modulating compounds used in glucose support systems was valued at between USD ~62.8 million in 2024 and projections indicate growth toward USD ~94.5 million by 2032 (CAGR ~5.3%), highlighting increased adoption across health-focused applications.
For manufacturers and ingredient buyers, these trends point to several application arenas:
- Dietary supplements and functional foods targeting postprandial glucose modulation, metabolic balance, and glycemic response support within wellness portfolios.
- Ingredient-driven product lines which leverage clinically supported mechanisms like α-glucosidase modulation to differentiate formulations in a competitive market.
- Geographic expansion into emerging markets, particularly Asia Pacific, where metabolic health awareness and ingredient adoption are growing rapidly.
Overall, the combination of sustained market growth in glucose management categories and expanding scientific validation for mechanism-based ingredients like DNJ HCl creates compelling opportunities for ingredient development, formulation innovation, and differentiated product positioning in health-oriented product lines.
Conclusion & Development Prospects
1-Deoxynojirimycin hydrochloride is a scientifically supported bioactive compound shown to help regulate glucose metabolism through specific α-glucosidase inhibition pathways. With an excellent safety profile and well-characterized mode of action, it stands out as a key ingredient for modern metabolic support nutraceuticals.
Future innovation opportunities lie in advanced delivery systems, targeted combinations with complementary metabolic support ingredients, and expanded applications in functional foods and personalized nutrition. These directions extend its role from traditional glucose management to comprehensive metabolic wellness support.
Whether you are developing new metabolic support formulations or enhancing existing nutraceutical products, võtke meiega ühendust for expert consulting guidance on achieving optimal product outcomes and premium market positioning with 1-deoxynojirimycin hcl applications.
Frequently Asked Questions
Q1. What formulation role does 1-deoxynojirimycin hydrochloride typically play in glucose-related products?
1-Deoxynojirimycin hydrochloride is primarily positioned as a digestive-phase carbohydrate modulation ingredient, targeting α-glucosidase activity. It is commonly used to complement downstream actives focused on insulin sensitivity or cellular glucose uptake within multi-mechanism formulations.
Q2. How does DNJ HCl support product differentiation for manufacturers?
DNJ HCl offers a clearly defined, single-compound mechanism with high standardization potential. This enables manufacturers to differentiate products through precision positioning, consistent performance, and transparent mechanism-based messaging rather than broad botanical claims.
Q3. What formulation formats are most suitable for 1-DNJ·HCl?
Due to its water solubility and neutral sensory profile, DNJ HCl is compatible with capsules, tablets, powders, and certain functional food or beverage applications. Its stability supports flexible use across multiple delivery systems.
Q4. What quality parameters should buyers prioritize when sourcing DNJ HCl?
Key considerations include purity level, batch-to-batch consistency, validated analytical methods, and supplier quality certifications. These factors are critical for maintaining formulation reproducibility and regulatory alignment across markets.
Q5. How is DNJ HCl typically positioned from a regulatory and claims perspective?
DNJ HCl is generally positioned under structure-function or nutritional support claims related to carbohydrate metabolism and postprandial glucose handling. Manufacturers should tailor claims language to regional regulations and avoid disease-treatment positioning.
